Nov
19
Jazz Pharma expects Xyrem announcement soon
Jazz Pharmaceuticals Inc. have cancelled a planned presentation because they anticipate releasing data from the first Phase III trial of JZP-6 (sodium oxybate) for the treatment of Fibromyalgia Syndrome within the next week.
more